¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"electrophoretic mobility shift assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme-linked immunosorbent assay
    È¿¼Ò°áÇո鿪ÈíÂøÃøÁ¤(¹ý)
  • foam stability assay
    °Åǰ¾ÈÁ¤ÃøÁ¤
  • hemagglutination assay
    Ç÷±¸ÀÀÁý°Ë»ç
  • hemizona assay index
    ¹ÝÅõ¸í¶ìÃøÁ¤ÁöÇ¥
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤(¹ý), ¿ëÇ÷ÇöóÅ©ÃøÁ¤(¹ý)
  • immunofluorescence assay
    ¸é¿ªÇü±¤ÃøÁ¤(¹ý), ¸é¿ªÇü±¤°Ë»ç
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤, ¸²ÇÁ±¸¼¼Æ÷µ¶¼º°Ë»ç
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤(¹ý), ÇöóÅ©ÃøÁ¤(¹ý)
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • radial partition immunofluorometric assay
    ¹æ»çºÐÇҸ鿪Çü±¤ÃøÁ¤
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antigenic shift
    Ç׿øº¯À§
  • axis shift
    ÃàÀ̵¿
  • chemical shift anisotropy
    È­Çк¯À§ºñµî¹æ¼º
  • chemical shift artifact
    È­Çк¯À§Àΰø¹°
  • phase shift artifact
    À§»óº¯À§Àΰø¹°
  • base line shift
    ±âÁؼ±À̵¿
  • chemical shift
    È­Çк¯À§
  • chemical shift imaging
    È­Çк¯À§¿µ»ó
  • chemical shift selection
    È­Çк¯À§¼±ÅÃ
  • chloride shift
    ¿°¼ÒÀ̵¿
  • Doppler shift
    µµÇ÷¯º¯À§
  • phase shift effect
    À§»óº¯À§È¿°ú
  • false shift
    °ÅÁþº¯À§
  • isodose shift method
    µî¼±·®À̵¿¹ý
  • isohydric shift
    µî¼ö¼ÒÀ̵¿
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • growth hormone assay
    ¼ºÀåÈ£¸£¸óÃøÁ¤
  • hemizona assay (index)
    ¹ÝÅõ¸í´ë ÃøÁ¤(ÁöÇ¥)
  • hemolytic plaque assay
    ¿ëÇ÷¹Ý ÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ© ÃøÁ¤¹ý
  • human zona binding assay
    »ç¶÷Á¤ÀÚ Åõ¸í´ëºÎÂø°Ë»ç
  • immunoconcentration assay
    ¸é¿ª³óÃàÃøÁ¤<--Á¤·®
  • immunoenzymometric assay
    ¸é¿ªÈ¿¼Ò°èÃø<--°è·®>ºÐ¼®
  • immunofluorescence assay
    ¸é¿ªÇü±¤°Ë»ç
  • immunometric assay
    ¸é¿ª°è·®<--°èÃø>°Ë»ç
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • plaque assay
    ÇöóÅ© ÃøÁ¤¹ý
  • plaque assay, hemolytic
    ¿ëÇ÷¼º ÇöóÅ© Çü¼º½ÃÇè
  • predictive assay
    È¿°ú¿¹Ãø½ÃÇè
  • radial partition immunofluorometric assay
    ¹æ»ê¼ººÐÇҸ鿪Çü±¤°èÃø¹ý
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤¹ý
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • phase shift
    À§»ó º¯À§
  • phase shift
    À§»óÀ̵¿(êÈßÓì¹ÔÑ).
  • phase shift artifact
    À§»ó º¯À§ Àΰø¹°
  • phase shift effect
    À§»ó º¯À§ È¿°ú
  • pivot shift test
    ÃßÃà º¯À§ ½ÃÇè
  • proton shift
    ¾ç¼ºÀÚÀ̵¿(åÕàõí­ì¹ÔÑ).
  • ribosomal frame shift
    ¸®º¸¼Ø ÇØµ¶Æ² º¯È¯
  • shift
    À̵¿
  • shift
    º¯À§, ÀÚ¸®º¸³»±â, ½ÃÇÁÆ®
  • shift
    À̵¿(ì¹ÔÑ), º¯À§(ܨêÈ).
  • shift key
    ½ÃÇÁÆ® Ű
  • shift work
    ±³´ë±Ù¹«, ¼øÈ¯±Ù¹«
  • shift work
    ±³´ëÀÛ¾÷(Ë´ËÀËöËâ).
  • shift work sleep disorder
    ±³´ë±Ù¹«¼ö¸éÀå¾Ö(º´)
  • stereo shift method
    Á¤À§À̵¿¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • competitive radioligand assay
    °æÇÕÀû(ÌæùêîÜ ¹æ»ç´É(Û¯ÞÒÒö)¸®°£µå ¾Æ½êÀÌ
  • continuous assay
    ¿¬¼Ó(Ö§áÙ)¾Æ½êÀÌ
  • coupled assay
    °ø¿ª(Íìæµ) ¾Æ¼¼ÀÌ (ÔÒ) auxiliary enzyme
  • d-assay
    d-¾Æ½êÀÌ
  • discontinuous assay
    ºÒ¿¬¼Ó(ÝÕææáÙ) ¾Æ½êÀÌ
  • dot blot assay
    Á¡(ïÃ)ºí·Ô ¾Æ¼¼ÀÌ
  • enzyme assay
    È¿¼Ò(ý£áÈ)¾Æ½êÀÌ
  • enzyme-linked immunosorbent assay
    È¿¼Ò¿¬°ü ¸é¿ªÈíÂø (ý£áÈ֤μØóæ¹ýåó·) ¾Æ½êÀÌ
  • fixed time assay
    ÀÏÁ¤½Ã°£(ìéïÒãÁÊà) ¾Æ½êÀÌ
  • hemolytic plaque assay
    ¿ëÇ÷(éÁúì) ÇöóÅ© ¾Æ½êÀÌ
  • i-assay
    i-¾Æ½êÀÌ
  • immunoenzymometric assay
    ¸é¿ªÈ¿¼ÒÃøÁ¤(Øóæ¹ý£áÈö´ïÒ) ¾Æ½êÀÌ
  • immunofluorometric assay
    ¸é¿ªÇü±¤ÃøÁ¤(Øóæ¹û«ÎÃö´ïÒ) ¾Æ½êÀÌ
  • immunoradiometric assay
    ¸é¿ª¹æ»ç´ÉÃøÁ¤(Øóæ¹Û¯ÞÒÒöö´ïÒ) ¾Æ½êÀÌ
  • in situ hybridization assay
    Á¦ÀÚ¸® Æ¢±â»ý¼º(ßæà÷) ¾Æ½êÀÌ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DRIP delirium and drugs-restricted mobility and retention-infection, inflammation and impaction-polyuria ...
EMD electromechanical dissociation; emergency medical dispacher; emergency medical doctor; Emery-Dreifus...
HMG high-mobility group; human menopausal gonadotropin; 3-hydroxy-3-methyl-glutaryl
LJM limited joint mobility; Lowenstein-Jensen medium
MOB mobility [scale]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CE Capillary electrophoretic
CZE Capillary zone electrophoretic
CSI Chemical Shift Imaging
CHESS Chemical shift selective
EMSA Electromobility shift assays
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • phase shift effect
    À§»ó º¯À§ È¿°ú
  • pivot shift test
    ÃßÃà º¯À§ ½ÃÇè
  • ribosomal frame shift
    ¸®º¸¼Ø ÇØµ¶ Ʋ º¯È¯
  • shift
    À̵¿, º¯À§
    À§Ä¡ »óÅÂÀÇ º¯È­.
  • shift ot left
    ÇÙ Á¹æ À̵¿
    È£Áß±¸ Áß À¯¾àÇüÀÇ °ÍÀ» ¿ÞÂÊ, ¼º¼÷ÇüÀÇ °ÍÀ» ¿À¸¥ÂÊ¿¡ µÎ¾î À¯¾àÇüÀÇ °ÍÀÌ ¸¹À¸¸é ÇÙ Á¹æ À̵¿À¸·Î Ç¥ÇöÇÑ´Ù.
  • shift system
    ±³´ëÁ¦ ±Ù¹«
    8½Ã°£ ÀÌ»óÀÇ ³ëµ¿À» ÇÊ¿ä·Î ÇÏ´Â Á÷Àå¿¡¼­ Á¶·Î ³ª´©¾î ÀÏÇÏ´Â Á¦µµ.
  • shift to right
    ¿ìÃø À̵¿
    Ç÷¾× »ó¿¡ À־ ¼º¼÷ Áß¼º±¸°¡ ¿ì¼¼ÇÑ °Í¿¡ ´ëÇÑ ArnethÀÇ ¿ë¾î.
  • shift to the right
    ¿ì¹æ À̵¿, ¿ì¹æ º¯À§, ¿ì°æ
    ÇÙ Á¹æ À̵¿ÀÇ ¹Ý´ë Çö»ó.
  • side-shift plate
    Bennett plates
    Whi
  • tube shift techique
    °ü±¸ À̵¿¼ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
bandshift assay <investigation> An assay for proteins, such as transcription factors, that bind specific DNA sequences.
A labelled oligonucleotide corresponding to the recognition sequence is incubated with an appropriate nuclear protein extract and run on a nondenaturing acrylamide gel. Oligonucleotides that have been bound by proteins are retarded relative to those that are unbound.
(18 Nov 1997)
biological assay <technique> Once a pharmaceutical protein is isolated from the cells in which it was grown, researchers perform tests to measure the protein's biological activity.
It must maintain a certain minimal level of biological activity to be used for animal or clinical testing or, later, for market. Researchers also test to confirm that the isolated protein is identical to the desired protein.
(21 Mar 1998)
radioimmunoprecipitation assay Sensitive assay using radiolabelled antigens to detect specific antibodies in serum. The antigens are allowed to react with the serum and then precipitated using a special reagent such as protein a sepharose beads. The bound radiolabelled immunoprecipitate is then commonly analyzed by gel electrophoresis. Radioimmunoprecipitation assay (ripa) is often used as a confirmatory test for diagnosing the presence of HIV antibodies.
(12 Dec 1998)
radioligand assay <radiobiology> Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labelled binding reagents (e.g., antibodies, intracellular receptors, plasma binders).
(12 Dec 1998)
radioreceptor assay A competitive binding assay in which the binder is a membrane or tissue receptor rather than an antibody.
(05 Mar 2000)
Raji cell radioimmune assay For immune complexes; a procedure by which immune complexes adsorbed from a test serum by a standard preparation of lymphoblastoid (Raji) cells are assayed by the capacity to bind 125I-labelled antibody to immunoglobulin.
(05 Mar 2000)
gel retardation assay A lab technique used to find out if there are proteins binding a fragment of DNA (in a DNA-protein complex) by watching how fast the DNA fragment moves through an electric field and seeing whether it moves slower when a particular protein is also present.
(09 Oct 1997)
checkerboard assay <procedure> Variant of the Boyden chamber assay for leucocyte chemotaxis introduced by Zigmond. By testing different concentrations of putative chemotactic factor in nongradient conditions, it is possible to calculate the enhancement of movement expected due simply to chemokinesis and to compare this with the distances moved in positive and negative gradients. Good experimental design thus allows chemotaxis to be distinguished from chemokinesis.
(21 May 1997)
chloramphenicol acetyltransferase assay <investigation> A lab technique used to determine whether a given fragment of DNA has a promoter on it to encourage transcription to occur, by attaching the gene (called the CAT gene) which codes for the CAT enzyme to it, and observing whether the CAT enzyme is produced.
(05 Jan 1998)
Grunstein-Hogness assay A procedure for identifying plasmid clones by colony hybridization.
(05 Mar 2000)
christmas factor assay A test used to measure the activity of a blood clotting factor IX (Christmas factor). This test may be used to evaluate excessive bleeding. Abnormally low factor IX assays may be seen in the following conditions: congenital deficiency of factor IX, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
clonogenic assay In vitro culturing of neoplastic cells to test their radiosensitivity or chemosensitivity, and probable clinical efficacy of a therapeutic agent.
(05 Mar 2000)
colony-forming units assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
(12 Dec 1998)
competitive binding assay General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards.
See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay.
Synonym: displacement analysis, saturation analysis.
(05 Mar 2000)
complement binding assay A test for the detection of immune complexes.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á